PL2424889T3 - Sposób wytwarzania przeciwciał domenowych - Google Patents

Sposób wytwarzania przeciwciał domenowych

Info

Publication number: PL2424889T3
Authority: PL; Poland
Prior art keywords: production; domain antibodies; antibodies; domain
Prior art date: 2009-04-30

Application number

PL10719752T

Other languages

English (en)

Inventor

Peter Schotte

Patrick Stanssens

Christine Labeur

Jean-Luc Jonniaux

Marc Jozef Lauwereys

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-30

Filing date

2010-04-30

Publication date

2016-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332495&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2424889(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-30 Application filed by Ablynx Nv filed Critical Ablynx Nv

2016-01-29 Publication of PL2424889T3 publication Critical patent/PL2424889T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

PL10719752T 2009-04-30 2010-04-30 Sposób wytwarzania przeciwciał domenowych PL2424889T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US17418409P	2009-04-30	2009-04-30
US30483410P	2010-02-16	2010-02-16
PCT/EP2010/055916 WO2010125187A2 (en)	2009-04-30	2010-04-30	Method for the production of domain antibodies
EP10719752.7A EP2424889B1 (en)	2009-04-30	2010-04-30	Method for the production of domain antibodies

Publications (1)

Publication Number	Publication Date
PL2424889T3 true PL2424889T3 (pl)	2016-01-29

Family

ID=42332495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10719752T PL2424889T3 (pl)	2009-04-30	2010-04-30	Sposób wytwarzania przeciwciał domenowych

Country Status (12)

Country	Link
US (2)	US9464138B2 (pl)
EP (3)	EP2424889B1 (pl)
AU (1)	AU2010243551B2 (pl)
CA (1)	CA2759370C (pl)
CY (1)	CY1124137T1 (pl)
DK (2)	DK2424889T3 (pl)
ES (2)	ES2864956T3 (pl)
HK (1)	HK1219741A1 (pl)
HU (1)	HUE053480T2 (pl)
PL (1)	PL2424889T3 (pl)
PT (1)	PT2424889E (pl)
WO (1)	WO2010125187A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2152747B1 (en)	2007-05-24	2018-01-03	Ablynx N.V.	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
HUE042053T2 (hu)	2008-06-05	2019-06-28	Ablynx Nv	Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
AU2015200057B9 (en) *	2009-06-05	2017-03-09	Ablynx Nv	Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) Nanobody constructs for the prevention and/or treatment of respiratory tract infections
MX340541B (es)	2009-06-05	2016-07-13	Alblynx Nv	Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EP2507262A1 (en)	2009-11-30	2012-10-10	Ablynx N.V.	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011161266A1 (en)	2010-06-25	2011-12-29	Ablynx Nv	Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
ES2660895T3 (es)	2010-10-29	2018-03-26	Ablynx N.V.	Método para la producción de dominios variables individuales de inmunoglobulina
PL2702164T3 (pl)	2011-04-29	2016-06-30	Biocon Res Limited	Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
US9670519B2 (en) *	2011-04-29	2017-06-06	Biocon Limited	Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012152823A1 (en)	2011-05-09	2012-11-15	Ablynx Nv	Method for the production of immunoglobulin single variable domains
RU2661677C2 (ru) *	2011-05-27	2018-07-18	Аблинкс Нв	Ингибирование резорбции кости с помощью связывающих rank-l пептидов
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
HUE050007T2 (hu)	2014-05-16	2020-11-30	Ablynx Nv	Immunglobulin variábilis domének
CN107406497A (zh) *	2014-12-19	2017-11-28	埃博灵克斯股份有限公司	半胱氨酸连接的纳米抗体二聚体
WO2016124781A1 (en) *	2015-02-05	2016-08-11	Ablynx N.V.	Nanobody dimers linked via c-terminally engineered cysteins
GB201506869D0 (en) *	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
US11046767B2 (en)	2015-05-13	2021-06-29	Ablynx N.V.	T cell recruiting polypeptides based on CD3 reactivity
RS59376B1 (sr)	2015-05-13	2019-11-29	Ablynx Nv	Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti
PT3334747T (pt) *	2015-08-13	2023-12-12	Amgen Inc	Formulação de gonadotrofina líquida estável
BR112018008754A2 (pt)	2015-10-30	2018-10-30	Ablynx Nv	polipeptídeo contra il-23
WO2017137579A1 (en)	2016-02-12	2017-08-17	Ablynx Nv	Method for the production of immunoglobulin single variable domains
KR102665596B1 (ko)	2016-11-16	2024-05-14	아블린쓰 엔.브이.	Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
EP3630847A1 (en)	2017-06-02	2020-04-08	Merck Patent GmbH	Adamts binding immunoglobulins
WO2019116310A1 (en) *	2017-12-13	2019-06-20	King Abdullah University Of Science And Technology	Functionalized polymeric membranes for the separation, recovery, and/or purification of antibodies
AR117650A1 (es) *	2018-10-11	2021-08-18	Amgen Inc	Procesamiento posterior de constructos de anticuerpos biespecíficos
WO2021198260A1 (en)	2020-03-30	2021-10-07	Ablynx Nv	Method for the production and purification of multivalent immunoglobulin single variable domains
AU2021402090A1 (en)	2020-12-18	2023-08-03	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity
US20240117038A1 (en)	2022-07-18	2024-04-11	Ablynx N.V.	Cx3cr1-binding compounds, methods and uses thereof
US20240132624A1 (en)	2022-07-27	2024-04-25	Ablynx N.V.	Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4572798A (en)	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
GB2270076A (en)	1992-08-18	1994-03-02	Univ Manchester	Human HSP 90 Epitopes
ES2338321T3 (es)	1992-08-21	2010-05-06	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
ATE204325T1 (de)	1993-04-29	2001-09-15	Unilever Nv	Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1997049805A2 (en)	1996-06-27	1997-12-31	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
DE69841562D1 (de)	1997-10-27	2010-04-29	Bac Ip Bv	Multivalente antigenbindende proteine
EP1051493A2 (en)	1998-01-26	2000-11-15	Unilever Plc	Method for producing antibody fragments
EP1141711A1 (en)	1999-01-05	2001-10-10	Unilever Plc	Binding of antibody fragments to solid supports
AU2291700A (en)	1999-01-19	2000-08-07	Unilever Plc	Method for producing antibody fragments
WO2000065057A1 (en)	1999-04-22	2000-11-02	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ES2331051T3 (es)	1999-11-29	2009-12-21	Bac Ip B.V.	Inmovilizacion de moleculas de union de antigenos de un dominio.
DK1242460T3 (da)	1999-11-29	2006-12-11	Unilever Nv	Immobilisering af proteiner ved hjælp af et polypeptidsegment
EP1134231B1 (en)	2000-03-14	2009-04-15	Unilever N.V.	Antibody heavy chain variable domains against human dietary lipases, and their uses
CA2380443C (en)	2000-05-26	2013-03-12	Ginette Dubuc	Single-domain antigen-binding antibody fragments derived from llama antibodies
ES2368623T3 (es)	2000-12-13	2011-11-18	Bac Ip B.V.	Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
WO2003025020A1 (fr)	2001-09-13	2003-03-27	Institute For Antibodies Co., Ltd.	Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP1456410A2 (en)	2001-12-11	2004-09-15	AlgoNomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en)	2001-12-21	2004-09-15	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Method for cloning of variable domain sequences
WO2003055527A2 (en)	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
AU2003301812A1 (en)	2002-11-01	2004-06-07	William L. Courtney	Variably configured inflatable personal flotation device also serving as an emergency distress marker
MXPA05004955A (es)	2002-11-08	2005-11-17	Ablynx Nv	Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
EP1558645B1 (en)	2002-11-08	2011-07-27	Ablynx N.V.	Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
CA2512545C (en)	2003-01-10	2015-06-30	Karen Silence	Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
JP2007521234A (ja)	2003-08-12	2007-08-02	ウィリアムエムヤーブロー	尋常性ざ瘡の治療薬及び使用方法
DE60334645D1 (de)	2003-11-07	2010-12-02	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084170A (ko)	2004-10-13	2007-08-24	아블린쓰 엔.브이.	알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
SG156672A1 (en)	2004-10-22	2009-11-26	Amgen Inc	Methods for refolding of recombinant antibodies
EP1819730A2 (en)	2004-11-30	2007-08-22	Novo Nordisk A/S	Method of producing antibodies
AU2005325801A1 (en)	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
PL2949668T3 (pl)	2005-05-18	2020-03-31	Ablynx N.V.	Ulepszone Nanobodies™ przeciwko czynnikowi martwicy nowotworów alfa
JP4986997B2 (ja)	2005-05-20	2012-07-25	アブリンクスエン．ヴェー．	凝集媒介障害の治療における改良ナノボディ（商標）
JP2008545781A (ja) *	2005-06-06	2008-12-18	ワイス	抗ＴｒｋＢモノクローナル抗体およびその使用
US7825223B2 (en)	2005-06-17	2010-11-02	Janssen Alzheimer Immunotherapy	Methods of purifying anti A β antibodies
WO2007136463A2 (en)	2006-04-07	2007-11-29	Dow Global Technologies Incorporated	Processes for improved disulfide bond formation in recombinant systems
AU2007285695B2 (en)	2006-08-18	2012-05-24	Ablynx N.V.	Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2666607C (en) *	2006-11-01	2015-02-10	Biogen Idec Ma Inc.	Method of isolating biomacromolecules using low ph and divalent cations
US20110118185A9 (en)	2007-02-21	2011-05-19	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EP2152747B1 (en)	2007-05-24	2018-01-03	Ablynx N.V.	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101932591B (zh) *	2007-07-09	2018-02-16	健泰科生物技术公司	在多肽的重组生产期间防止二硫键还原
EP2215125A1 (en)	2007-11-27	2010-08-11	Ablynx N.V.	Method for obtaining polypeptide constructs comprising two or more single domain antibodies

2010
- 2010-04-30 CA CA2759370A patent/CA2759370C/en active Active
- 2010-04-30 PT PT107197527T patent/PT2424889E/pt unknown
- 2010-04-30 DK DK10719752.7T patent/DK2424889T3/en active
- 2010-04-30 ES ES15174570T patent/ES2864956T3/es active Active
- 2010-04-30 ES ES10719752.7T patent/ES2551854T3/es active Active
- 2010-04-30 US US13/266,503 patent/US9464138B2/en active Active
- 2010-04-30 AU AU2010243551A patent/AU2010243551B2/en active Active
- 2010-04-30 DK DK15174570.0T patent/DK2982690T3/da active
- 2010-04-30 WO PCT/EP2010/055916 patent/WO2010125187A2/en active Application Filing
- 2010-04-30 EP EP10719752.7A patent/EP2424889B1/en active Active
- 2010-04-30 PL PL10719752T patent/PL2424889T3/pl unknown
- 2010-04-30 EP EP20216389.5A patent/EP3828201A1/en active Pending
- 2010-04-30 EP EP15174570.0A patent/EP2982690B1/en active Active
- 2010-04-30 HU HUE15174570A patent/HUE053480T2/hu unknown
2016
- 2016-07-04 HK HK16107739.3A patent/HK1219741A1/zh unknown
- 2016-09-01 US US15/254,027 patent/US20170081692A1/en active Pending
2021
- 2021-04-07 CY CY20211100300T patent/CY1124137T1/el unknown

Also Published As

Publication number	Publication date
CY1124137T1 (el)	2022-05-27
AU2010243551A1 (en)	2011-11-10
HK1219741A1 (zh)	2017-04-13
EP3828201A1 (en)	2021-06-02
DK2424889T3 (en)	2015-11-02
US20120157664A1 (en)	2012-06-21
EP2424889A2 (en)	2012-03-07
EP2424889B1 (en)	2015-08-12
EP2982690A1 (en)	2016-02-10
WO2010125187A2 (en)	2010-11-04
CA2759370A1 (en)	2010-11-04
CA2759370C (en)	2020-02-11
ES2551854T3 (es)	2015-11-24
US9464138B2 (en)	2016-10-11
PT2424889E (pt)	2015-11-12
ES2864956T3 (es)	2021-10-14
EP2982690B1 (en)	2021-01-27
HUE053480T2 (hu)	2021-06-28
AU2010243551B2 (en)	2015-03-26
US20170081692A1 (en)	2017-03-23
DK2982690T3 (da)	2021-04-12
WO2010125187A3 (en)	2011-01-20

Publication	Publication Date	Title
HK1219741A1 (zh)	2017-04-13	結構域抗體的生產方法
HUE051430T2 (hu)	2021-03-01	Eljárás variábilis domének elõállítására
PT2913337T (pt)	2017-11-28	Processo para a produção de sofosbuvir
ZA201202504B (en)	2013-06-26	Process for the preparation of calcobutrol
EP2462088A4 (en)	2014-04-09	PROCESS FOR THE PRODUCTION OF METHANE
HK1179272A1 (en)	2013-09-27	Process for obtaining antibodies
PL390042A1 (pl)	2011-07-04	Sposób wytwarzania kwasu chlebowego
IL216942A0 (en)	2012-02-29	Process for the manufacture of alkenones
IL224318B (en)	2018-06-28	A method for the automated synthesis of small molecules
IL240122B (en)	2019-02-28	A method for producing an antibody
SI2253608T2 (sl)	2021-11-30	Postopek za izdelavo razvejenih nasičenih ogljikovodikov
EP2221384A4 (en)	2011-04-06	METHOD FOR MANUFACTURING ANTIBODY
PL388931A1 (pl)	2011-03-14	Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
GB0914589D0 (en)	2009-09-30	Novel compounds and methods for their production
PL385356A1 (pl)	2009-12-07	Sposób wytwarzania tadalafilu
GB2480419B (en)	2014-09-17	Method for the manufacture of ethanol
PL2435448T3 (pl)	2014-07-31	Sposób wytwarzania dialkilofosforynów
GB0904540D0 (en)	2009-04-29	Novel compounds and methods for their production
GB0917817D0 (en)	2009-11-25	Novel compounds and methods for their production
IL220160A (en)	2016-12-29	A process for the preparation of defrasirox
PL389568A1 (pl)	2011-05-23	Sposób otrzymywania 2-metyloglicydolu
GB0904542D0 (en)	2009-04-29	Novel compounds and methods for their production
GB0917816D0 (en)	2009-11-25	Novel compounds and methods for their production
GB0802615D0 (en)	2008-03-19	Method of production
GB201000454D0 (en)	2010-02-24	Process for the production of hydrocarbons